Publication details
Možnosti studia synergismu protinádorové imunoterapie s vybranými léčivy
| Title in English | Opportunities for Studying Synergism in Anticancer Immunotherapy with Selected Drugs |
|---|---|
| Authors | |
| Year of publication | 2025 |
| Type | Appeared in Conference without Proceedings |
| MU Faculty or unit | |
| Citation | |
| Description | Antitumor immunotherapy is a modern approach to cancer treatment. Its antitumor effect is based on the inhibition of immune system checkpoints. Inhibiting these proteins restores the function of T-lymphocytes, thereby enhancing the immune response to the tumor. Although checkpoint inhibitors are widely used as registered anticancer drugs, they often lead to an insufficient patient response to treatment or the development of resistance. Therefore, approaches to enhance checkpoint inhibitors effects are under study. One possibility is to interfere with signaling pathways such as JAK/STAT, PI3K/AKT/mTOR, WNT/ß-catenin and others, which are often responsible for developing resistance to antitumor immunotherapy. In our experimental research, we focused on the JAK/STAT signaling pathway and the inhibition of phosphorylation of STAT3 protein, which regulates PD-L1 expression in tumor cells. To study the synergistic effect of antitumor immunotherapy with STAT3 inhibitors, we developed an in vitro co-cultivation model of of activated T-lymphocytes with a tumor cell line that expresses the PD-L1 ligand and a antitumor immunotherapy representative. |
| Related projects: |